TOPRA is supporting the Global Pharma Regulatory Summit 2024

Posted on 22 May 2024

TOPRA has been confirmed as a supporter of the 13th Annual Global Pharma Regulatory Summit being held by Informa. Taking place between 19 and 21 June 2024 in Mumbai, India, this conference is the premier pharma regulatory event for the Indian generics and biosimilars industries.

With the theme of ‘Harmonizing regulatory policies for ensuring safety, efficacy, and quality of drugs worldwide’, this 3-day conference will bring together regulatory operations and submission professionals to share best practice in the compilation, formatting, and submission of a variety of approval applications.  

Each day focuses on a specific geographical region as follows:

  • Day 1: US & Latin America Landscape
  • Day 2: UK & EU Regulatory Landscape
  • Day 3: Rest of the World Overview

We are proud to announce that we are chairing the second day of the conference, where topics to be discussed will include:

  • Regulatory considerations for Real World Evidence (RWE) and Big Data
  • Clinical Trials Regulation (CTR), Clinical Trials Information System (CTIS) and Accelerating Clinical Trials (ACT)
  • Innovative therapies: the future of personalised and precision health
  • Artificial intelligence (AI) in pharmaceutical regulatory affairs

Speakers include Dr Sumit Sant from Novatris, Dr Anil Kukreja from AstraZeneca, Dr Maya Sharma from Novo Nordisk, Rashmi Hegde from GSK, Dr Vaibhav Salvi from Sanofi and many more.

As an event supporter, we have also arranged for TOPRA members to get a 5% discount on registration fees. To claim your discounted rate, please enquire using this online form and mention that you are a TOPRA member in the subsequent correspondence. 

TOPRA Chief Executive, Kevin Pay, said: “We are delighted to join the Global Pharma Regulatory Summit 2024’s roster and to support this important event for pharmaceutical professionals in India. We at TOPRA are committed to assisting regulatory affairs professionals worldwide. We view our participation as an excellent opportunity to forge new connections with pharmaceutical colleagues and organisations."